Labcorp Holdings (N6B) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Biopin-6 Active Implant With Naltrexone | Opioid Use Disorder | Phase I | Completed | Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults | Dec 27, 2023 | ― |
| ensifentrine | Chronic Obstructive Pulmonary Disease | Phase III | Completed | A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Feb 14, 2023 | ― |
| Static - Pet/Ct Scan, Geh121224 (18F) Injection, Dynamic And Static - Pet/Ct Scan | Breast Cancer | Phase I | Withdrawn | Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer | Nov 22, 2022 | ― |
| Ocrelizumab | Multiple Sclerosis, Clinically Isolated Syndrome | Phase IV | Completed | A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab | Aug 06, 2021 | ― |
| Ocrelizumab | Multiple Sclerosis, Clinically Isolated Syndrome | Phase IV | Completed | A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy | Aug 06, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Biopin-6 Active Implant With Naltrexone | Phase I | Opioid Use Disorder | Completed | Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults | Dec 27, 2023 | ― |
| ensifentrine | Phase III | Chronic Obstructive Pulmonary Disease | Completed | A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Feb 14, 2023 | ― |
| Static - Pet/Ct Scan, Geh121224 (18F) Injection, Dynamic And Static - Pet/Ct Scan | Phase I | Breast Cancer | Withdrawn | Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer | Nov 22, 2022 | ― |
| Ocrelizumab | Phase IV | Multiple Sclerosis, Clinically Isolated Syndrome | Completed | A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab | Aug 06, 2021 | ― |
| Ocrelizumab | Phase IV | Multiple Sclerosis, Clinically Isolated Syndrome | Completed | A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy | Aug 06, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Labcorp Holdings Inc. (DE:N6B) have in its pipeline
Labcorp Holdings DE:N6B is currently developing the following drugs: Biopin-6 Active Implant With Naltrexone, ensifentrine, Static - Pet/Ct Scan, Geh121224 (18F) Injection, Dynamic And Static - Pet/Ct Scan, Ocrelizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.